No connection

Search Results

HHS

BEARISH
$2.36 Live
Harte Hanks, Inc. · NASDAQ
$2.22 52W Range $5.39

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 11, 2026
Market cap
$17.53M
P/E
N/A
ROE
-3.8%
Profit margin
-0.5%
Debt/Equity
1.09
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
HHS exhibits severe financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. The company is trapped in a cycle of contracting revenues (-15.40% YoY) and negative profitability, with a long-term price collapse of over 73% over three years. While the stock trades at a low Price-to-Book (0.85) and Price-to-Sales (0.11), these metrics appear to be a value trap rather than a discount, given the operational decay. The lack of analyst coverage and neutral insider activity further suggest a lack of institutional confidence.

Key Strengths

Price-to-Book ratio below 1.0 (0.85)
Extremely low Price-to-Sales ratio (0.11)
Current Ratio of 1.54 indicates short-term liquidity is currently maintained
Quick Ratio of 1.34 suggests reasonable ability to cover immediate liabilities
Positive Gross Margin (17.32%)

Key Risks

Piotroski F-Score of 0/9 indicates critical fundamental weakness
Consistent revenue contraction (-15.40% YoY and -15.43% Q/Q)
Negative Return on Equity (-3.84%) and negative profit margins
Severe long-term price depreciation (5Y Change: -47.9%)
Micro-cap status ($0.02B) increases volatility and liquidity risk
AI Fair Value Estimate
Based on comprehensive analysis
$1.85
-21.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
9
Weak
Value
30
Future
5
Past
10
Health
0
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: 0/9 Piotroski Score, Negative Revenue Growth, Long-term Bearish Price Trend
Confidence
90%
Value
30/100

Trades below book value, but fundamentals do not support a recovery.

Positives
  • Low P/B ratio
  • Low P/S ratio
Watchpoints
  • Forward P/E is suspiciously low, likely reflecting non-recurring items or unsustainable projections
Future
5/100

Revenue Growth (YoY): -15.40%

Positives
No standout positives identified.
Watchpoints
  • Double-digit revenue decline
  • Negative EPS growth
Past
10/100

Consistent downward trajectory across 1Y, 3Y, and 5Y timeframes.

Positives
No standout positives identified.
Watchpoints
  • 3-year price decline of 73.6%
  • Highly volatile earnings surprises
Health
0/100

The 0/9 F-Score is a definitive signal of financial deterioration.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
  • Negative ROE
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.36

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HHS and closest competitors.

Updated 2026-04-10
HHS
Harte Hanks, Inc.
Primary
5Y
-47.9%
3Y
-73.6%
1Y
-46.0%
6M
-34.9%
1M
-13.7%
1W
-5.4%
AER
Aeries Technology, Inc
Peer
5Y
-95.8%
3Y
-96.0%
1Y
-32.3%
6M
-32.3%
1M
-17.3%
1W
+40.5%
BTO
Armlogi Holding Corp.
Peer
5Y
-93.2%
3Y
-93.2%
1Y
-68.4%
6M
-65.6%
1M
+9.4%
1W
+24.2%
EHL
Euroholdings Ltd.
Peer
5Y
-53.9%
3Y
-53.9%
1Y
+81.4%
6M
+9.8%
1M
+6.4%
1W
-0.8%
ACC
Acco Group Holdings Limited
Peer
5Y
-62.5%
3Y
-62.5%
1Y
-62.5%
6M
-62.5%
1M
+7.0%
1W
-5.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
2.21
PEG Ratio
N/A
P/B Ratio
0.85
P/S Ratio
0.11
EV/Revenue
0.21
EV/EBITDA
6.32
Market Cap
$17.53M

Profitability

Profit margins and return metrics

Profit Margin -0.51%
Operating Margin -0.4%
Gross Margin 17.32%
ROE -3.84%
ROA 0.62%

Growth

Revenue and earnings growth rates

Revenue Growth -15.4%
Earnings Growth N/A
Q/Q Revenue Growth -15.43%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.09
Moderate
Current Ratio
1.54
Good
Quick Ratio
1.34
Good
Cash/Share
$0.75

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
70.6%
Op. Margin
0.4%
Net Margin
5.5%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
3.47x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
-93%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-16
$N/A
2024-11-14
$0.02
-80.0% surprise
2024-05-10
$0.06
+249.2% surprise
2024-03-14
$0.12
-0.5% surprise

Industrials Sector Comparison

Comparing HHS against 199 companies in the Industrials sector (16 bullish, 81 neutral, 102 bearish)
Return on Equity (ROE)
-3.84%
This Stock
vs
-4.57%
Sector Avg
-15.8% (Below Avg)
Profit Margin
-0.51%
This Stock
vs
26.28%
Sector Avg
-101.9% (Weaker)
Debt to Equity
1.09
This Stock
vs
3.99
Sector Avg
-72.7% (Less Debt)
Revenue Growth
-15.4%
This Stock
vs
30.91%
Sector Avg
-149.8% (Slower)
Current Ratio
1.54
This Stock
vs
3.11
Sector Avg
-50.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

RADOFF BRADLEY LOUIS
Director
Stock Award
2025-12-09
27,861 shares · $89,991
COMBES GENEVIEVE CLAIRE
Director
Stock Award
2025-12-09
27,861 shares · $89,991
Insider transactions can signal confidence or concerns about company prospects

Past News Coverage

Recent headlines mentioning HHS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile